8-K: Kairos Pharma's ENV105 Shows Strong Prostate Cancer Efficacy

Kairos Pharma announced positive interim efficacy data from its Phase 2 clinical trial of ENV105 in metastatic castration-resistant prostate cancer, showing a median progression-free survival of over 13 months.

Summary

• Positive interim efficacy data from the ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) has been announced.
• The median progression-free survival (PFS) was over 13 months for 8 evaluable patients, significantly exceeding the trial's target of 6.7 months.
• Five of the eight evaluable patients are continuing treatment without progression.
• Seven of nine patients demonstrated a decrease in their prostate-specific antigen (PSA) from baseline.
• ENV105, a first-in-class CD105 antagonist, was combined with standard of care hormone therapy apalutamide.
• All patients enrolled in this interim analysis had previously failed at least one other hormone therapy modality.
• A virtual Key Opinion Leader (KOL) event is scheduled for September 18, 2025, at 5 p.m. ET / 2 p.m. PT to provide additional perspectives on this data.

Sentiment

Score: 9

Explanation: The interim Phase 2 efficacy data for ENV105 in mCRPC is exceptionally positive, demonstrating a median progression-free survival significantly exceeding both the trial's target and current standard of care, coupled with a favorable safety profile. This represents a strong clinical signal for a novel therapeutic in an area of high unmet medical need.

Positives

• Median progression-free survival (PFS) of over 13 months significantly exceeded the trial's target of 6.7 months, which represents a 45% improvement over the 3.7 months median efficacy of 2nd or 3rd line standard of care hormone therapy.
• Five out of eight evaluable patients are continuing treatment without progression, indicating sustained benefit.
• Seven out of nine patients demonstrated a decrease in their prostate-specific antigen (PSA) from baseline, a key indicator of treatment response.
• ENV105 was well tolerated when combined with standard of care apalutamide, with no dose-limiting toxicities or unexpected adverse events reported in the interim safety analysis (July 2025).
• No Grade 3 or Grade 4 toxicities were observed, suggesting a favorable safety profile compared to other treatments like chemotherapy.

Negatives

• The efficacy data is interim and based on a small cohort of 8 evaluable patients (out of 10 initially enrolled), which may not be fully representative of a larger population.
• Two of the ten initial patients withdrew from the trial for unrelated events, reducing the evaluable patient count.

Risks

• Underlying assumptions in forward-looking statements may prove inaccurate, leading to actual results varying materially from expectations.
• Known or unknown risks or uncertainties could materialize, causing actual results to differ materially from projections.
• Challenges and uncertainties are inherent in product research and development, including the success and completion of clinical trials and obtaining regulatory approval.
• There is uncertainty regarding future commercial success of ENV105.
• Actual events and results may differ materially due to risks, uncertainties, and assumptions described in Kairos Pharma's Annual Report on Form 10-K and other SEC filings.

Future Outlook

Kairos Pharma aims to revolutionize cancer treatment by targeting cancer resistance. The company is continuing to accrue patients for the randomized Phase 2 trial, which aims to enroll 100 patients in total, and is also conducting a Phase 1 trial for lung cancer. Management expects to lay out the primary benefits of ENV105 and demonstrate its clinical need at the upcoming KOL event.

Management Comments

• "Our therapeutics, targeting cancer resistance, continue to showcase the potential to revolutionize the way we treat cancer patients." Dr. John Yu, CEO of Kairos Pharma.
• "While this is only interim data, we are excited to bring together the principal investigators and other industry experts for an important event this afternoon to lay out the primary benefits of our compound, and demonstrate the clinical need filled by ENV105." Dr. John Yu, CEO of Kairos Pharma.

Industry Context

The development of resistance to current hormone therapies for prostate cancer has created a growing unmet medical need, particularly with an increasingly aging population. Current treatment options remain limited after hormone therapies fail. Kairos Pharma's ENV105, a CD105 antagonist, aims to address this by reversing drug resistance and restoring the effectiveness of standard therapies, potentially offering a safe and effective alternative for patients with metastatic castration-resistant prostate cancer.

Comparison to Industry Standards

• The ENV105/Apalutamide combination achieved a median progression-free survival (PFS) of over 13 months, significantly exceeding the 3.7 months median efficacy of 2nd or 3rd line standard of care hormone therapy as reported by the CARD trial.
• The observed PFS also surpassed the 8 months PFS achieved by chemotherapy (cabazitaxel) in the CARD study, notably with ENV105 showing no Grade 3 or Grade 4 toxicities compared to chemotherapy's greater toxicity.
• The trial was powered to show a 45% improvement in PFS, translating to an increase from 3.7 to 6.7 months, a mark far exceeded by the ENV105/Apalutamide combination.

Stakeholder Impact

• Shareholders: The highly positive interim clinical data could lead to increased investor confidence and potential share price appreciation due to the significant therapeutic potential.
• Patients with mCRPC: This offers potential for a new, more effective, and better-tolerated treatment option for a disease with limited alternatives after standard hormone therapies fail.
• Medical Community: The new data provides valuable insights into a novel therapeutic approach for mCRPC, potentially influencing future treatment paradigms and clinical practice.
• Employees: Positive clinical progress can boost morale, validate research efforts, and attract top talent to the company.

Next Steps

• Host a virtual KOL event on September 18, 2025, at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the interim efficacy results.
• Continue accruing patients for the randomized Phase 2 trial, which aims to enroll 100 patients in total, at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Center.
• Continue the Phase 1 trial for lung cancer.

Key Dates

Recommendation

The interim Phase 2 efficacy data for ENV105 in mCRPC demonstrates a median progression-free survival of over 13 months, significantly exceeding both the trial's target of 6.7 months and the 3.7 months for standard of care hormone therapy. This strong efficacy, coupled with a favorable safety profile (no Grade 3/4 toxicities), suggests a highly promising therapeutic candidate addressing a significant unmet medical need. While it is interim data from a small cohort, the magnitude of the benefit compared to existing treatments warrants a strong positive outlook and potential for substantial future value creation for this clinical-stage biopharmaceutical company.

Keywords

Kairos Pharma, KAPA, ENV105, carotuximab, prostate cancer, mCRPC, metastatic castration-resistant prostate cancer, Phase 2 clinical trial, CD105 antagonist, oncology, biopharmaceutical, PFS, progression-free survival, apalutamide, cancer therapeutics